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Introduction
Atopic eczema is a common skin disease, often manifesting 
in early childhood in the majority of patients. About 50% are 
affected in the first year of life, and a further 15% in the first 
five years1. It often occurs in association with other allergic 
conditions such as asthma, hay fever, allergic rhinitis and 
allergic conjuctivitis. The aetiology involves a complex 
interplay between genetic factors, disrupted skin barrier 
function, a food allergy, and many other extrinsic factors 
like skin irritants, inhalant allergens and superficial bacterial 
infections of the skin.2 The pathogenesis is a complex 
inflammatory process involving cellular and immunological 
processes, but T-lymphocyte activation plays a central role.3
Discussion
The clinical presentation varies with the different stages of 
life. In infants, the disease affects the entire body, and has 
no specific distribution (see Figure 1). In younger children, 
the lesions are usually on extensors surfaces of the limbs, 
that is, the elbows and the knees (see Figure 2). In older 
children and adults, lesions usually appear on the flexors 
surfaces of the limbs, that is, the cubital and popliteal fossae 
(see Figure 3). However, distribution of the lesions does not 
always follow this pattern.
Clinical features include erythema, oedema, vesiculation, 
crusting, dryness, scaling, excoriations and lichenification. 
Pruritus is a chief symptom, and can be very troublesome. 
Children with atopic eczema are more prone to bacterial 
and viral infections of the skin. The most common bacterial 
infection is due to Staphylococcus aureus, causing folliculitis, 
impetigo or even ecthyma.4 It has been shown that 90% of 
patients with atopic eczema are colonised with S. aureus. 
A direct relationship between the disease activity and the 
degree of colonisation has been shown.5 Patients with atopic 
eczema are also prone to infection with herpes simplex virus, 
causing a condition called eczema herpeticum, or Kaposi’s 
varicelliform eruption.6 Susceptibility to these infections 
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Atopic eczema is a chronic, relapsing inflammatory disease of the skin. It is characterised by dry, itchy skin and a typical 
distribution on the elbows and knees in younger children, and the cubital and popliteal fossae in older children and adults. 
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Figure 2: Atopic eczema in a two-year old. Note the distribution on 
the knees. This patient has lesions on the elbows as well.
Figure 1: Atopic eczema in a six-month-old baby
Figure 3: Atopic eczema in an older child. Note the distribution on 
cubital fossae. This patient has lesions on the popliteal fossae as well. 
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seems to be related to disrupted skin barrier function, and 
possibly the use of systemic and topical steroids, although 
this is not always the case. Topical corticosteroids should be 
temporarily stopped while these infections are treated.
Topical treatments
Emollients
The dryness in eczema worsens the disease. Therefore, 
regular use of emollients is important. Emollients maintain 
hydration of the skin, and may even protect against 
inflammation provoked by irritants. These emollients should 
be applied as frequently as possible throughout the day.7 
Although there are no clear randomly controlled trials 
showing evidence of the benefits of emollients in atopic 
eczema, there is currently no evidence to doubt that their 
regular use is beneficial for the treatment of the dry skin, and 
the barrier defect that is associated with atopic eczema.4,8 
Topical corticosteroids
Despite their side-effects, topical corticosteroids still remain 
the mainstay of atopic eczema treatment. Anxiety relating 
to steroid phobia among the general public and doctors 
has led to undertreatment of many patients with atopic 
dermatitis.7 When prescribing topical corticosteroids, 
factors to be considered are the patient’s age, the site to 
be treated, severity of the eczema, and the potency of the 
preparation.9 Generally, mild potency corticosteroids, such 
as 1% hydrocortisone, are suitable for use on the face. More 
potent corticosteroids are used to treat flare-ups of severe 
disease, and should be used for a limited period only.4 Skin 
atrophy is not problematic if these preparations are used 
correctly.8 When treating areas like the face, eyelids, breasts, 
thighs and flexures, special attention should be made when 
choosing the potency of topical corticosteroids. There 
are various vehicles in which corticosteroids preparations 
are contained, e.g. lotions, creams, gels, foams, and fatty 
ointments. Since eczema is a dry skin disease, ointments 
are generally preferred because they increase percutaneous 
absorption by increasing hydration of the skin.
Calcineurin inhibitors
Topical calcineurin inhibitors are a major advance in the 
management of atopic eczema. They inhibit inflammatory 
cytokine transcription in activated T cells and other 
inflammatory cells, through inhibition of calcineurin.10 The 
two available preparations are pimecrolimus and tacrolimus.
Pimecrolimus is an ascomycin macrolactum derivative and 
a selective inhibitor of the production and release of pro-
inflammatory cytokines and mediators of T cells and mast 
cells. It is available in a preparation of 1%, and is indicated 
for the treatment of mild to moderate atopic dermatitis, 
especially for steroid-sensitive areas like the face and skin 
folds.4,11 It can be used in patients as young as two years 
of age. It effectively controls the acute signs of eczema, 
especially on the face, and prevents flares in mild, moderate 
and severe eczema. It can be used singly, or in combination 
with topical steroids. Pimecrolimus has a strong anti-
inflammatory effect, favourable safety profile, and is well 
tolerated.
Tacrolimus is a macrolide lactone isolated from the 
fermentation product of Streptomyces tsukubaensis. It has 
potent and selective immunosuppressant activity, inhibiting 
T helper cells, cytokines, mast cells and basophils.9 It is 
available in preparations of 0.03% and 0.1%, and is indicated 
for the treatment of moderate to severe eczema. Tacrolimus 
is also indicated for use in the face and intertrigenous area.12 
The 0.03% preparation can be used in children older than 
two years, and the 0.1% preparation in those older than 
15 years.4 Tacrolimus has a strong anti-inflammatory effect, 
favourable safety profile, and is well tolerated.
Tar preparations
Tar preparations have been used in the form of bath 
solutions, creams, ointments and paste bases to treat atopic 
eczema lesions, but their potential carcinogenic effects have 
made their use less fashionable.9
Antiseptics
These products are used to decrease skin colonisation by 
S. aureus. The ideal antiseptic should be effective in reducing 
S. aureus colonisation, non-irritating to eczematous skin, and 
non-sensitising. One should also establish that the antiseptic 
is bactericidal at the concentration used.9 Topical antibiotics 
should only be used to treat clinically infected lesions. They 
should not be used in an attempt to reduce staphylococcal 
colonisation, as this may lead to the emergence of 
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